Benny Bang-Andersen, MSc (pharm), MSc (chemistry), PhD, has been working at H. Lundbeck A/S with drug discovery within the central nervous system field for more than 15 years. Dr. Bang-Andersen started at Lundbeck as a PhD student in 1993 under the supervision of Professor Povl Krogsgaard-Larsen and Dr. Klaus P. Bøgesø. In 2006 he became the associate director of medicinal chemistry research. In 2009, Dr. Bang-Andersen became chief scientist in medicinal chemistry, and he is currently leading a medicinal chemistry group, as well as driving the discovery and development of positron emission tomography (PET) ligands, supporting drug development programs.

Dr. Bang-Andersen’s research activities have focused on drug and PET ligand design and development within psychiatric and neurologic diseases. These research activities have resulted in more than 60 articles and patent applications, as well as the nomination of several drug candidates, of which Lu AA24530 and Lu AA21004 are in phase II and III, respectively.